- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01077349
High Volume Veno-venous Hemofiltration Versus Standard Care for Post-cardiac Surgery Shock (HEROICS)
Early Continuous High Volume Veno-venous Hemofiltration vs. Standard Care for Post-cardiac Surgery Shock Requiring High Doses Catecholamines. The HEROICS Study: HEmofiltration to Rescue Severe shOck followIng Cardiac Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Title - Early continuous high volume veno-venous hemofiltration vs. standard care for post-cardiac surgery shock requiring high dose catecholamines. An open label randomized multicenter controlled trial. The HEROICS Study: HEmofiltration to Rescue severe shOck followIng Cardiac Surgery.
Clinical Phase - III Study Rationale - Systemic inflammatory response syndrome associated with cardiac surgery under cardiopulmonary bypass (CPB) shares many pathophysiologic features of septic shock and post-resuscitation syndrome. Since high volume hemofiltration has been shown to markedly improve hemodynamic profile and survival in these situations, there is a strong rationale for testing, with an adequately powered randomized controlled trial, this purification technique in patients developing post-cardiac surgery shock requiring high doses catecholamine.
Trial Design -
The proposed study will compare high volume hemofiltration (80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery to standard treatment, where extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h) will be initiated only if the following criteria are met:
- Serum creatinine > 350 micromol/L or increase x3.0 from pre-operative value OR
- Diuresis < 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR
- Or serum urea > 36 mmol/l OR
- Or life threatening hyperkalemia. In the experimental arm, hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + norepinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being 35 ml/kg/h (or a maximum of 3500 ml/h).
Subject Participation - 90 days
Rationale for Number of Subjects - The study will follow a sequential analytical plan with stopping rules based on the triangular test. The expected mortality of the control group is expected to be 25% and the expected absolute mortality reduction with the experimental treatment of 12%. For 80% power and a 5% α-risk, the study characteristics, calculated with the triangular test, are as follows: a maximum of 540 subjects to be included and a 90% probability of stopping the study before 330 subjects have been included. With an inclusion rate of 120-150 patients per year, the maximum duration of the study is 2 years and 3 months and the probability of stopping the study before 18 months is 90%.
Approximate duration of Study - 27 months
Study Objective(s) Primary - The primary study outcome is death from all causes at 30 days after randomisation.
Secondary
- Mortality 60 and 90 days following study enrollment
- ICU and Hospital mortality
- Mortality adjusted on the type of surgery and patient severity at randomization
- Duration of catecholamine infusion and number of catecholamine-free days at 30 days following study enrollment
- Duration of renal replacement therapy and number of renal replacement therapy -free days at 30 days following study enrollment
- Recovery of renal failure and dialysis independent survival
- Duration of mechanical ventilation and number of mechanical ventilation -free days at 30 days following study enrollment
- SOFA score on days 1, 2 ,3 ,4 ,7 ,15 , and 30 following study enrollment
- Reduction in markers of overt coagulation and inflammation at days 2, 4 and 7 following study enrollment
- ICU and Hospital length of stay
- Mortality analysis according to subgroups of patients (type of surgery, severity at randomization, renal function at randomization)
Approximate Number of Subjects - 330
Approximate Number of Study Centres - 8 centres distributed in France will participate in the study.
Treatment Administration - Each participant will be randomised to receive high volume hemofiltration (CVVH, 80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery or standard treatment, where extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h) will be initiated only if criteria for renal failure are met.
Safety Evaluation - Safety for individual patients will be assessed on an ongoing basis by physical examination, including vital signs, outputs from dialysis machine records, laboratory assessments, and monitoring of adverse events. Overall study safety will be ensured by an Independent Data Safety Monitoring Committee, independent from all Trial investigators, which will perform ongoing review of predefined safety parameters and study conduct.
Efficacy Evaluation - Overall survival at 30 days post randomisation
Statistical Analysis - The first analysis is scheduled after the inclusion of 60 subjects. Thereafter, stopping rules are scheduled to be sequentially applied, based on the triangular test. This will allow us to stop the trial as soon as there are sufficient evidence that one of the 2 treatment strategies are more dangerous or that there was no longer a chance of demonstrating the postulated treatment difference of 12%, while controlling the risks of type I and II errors. Sequential analyses will be conducted every 20 patients. The baseline and outcome variables will be compared using Students t test, Chi squared and the Mann-Whitney U test as appropriate. Kaplan-Meier survival curves for the 30 days following randomization will be compared with a log-rank test., with survival being calculated from the date of randomization.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Groupe Hospitalier Pitie-Salpetriere
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cardiac surgery with cardiopulmonary bypass
Patient still on high doses catecholamines 3 to 24 hours following cardiac-surgical ICU admission. High doses catecholamines is defined by IV infusion of :
- Epinephrine >0.2 microg/kg/min or
- Norepinephrine >0.4 microg/kg/min or
- Epinephrine + (Norepinephrine /2) >0.2 microg/kg/min
- Cardiac assistance using ECMO/ECLS technique are considered equivalent to high doses catecholamines.
- Informed consent has been obtained from next of kin or when consent cannot be obtained, the intervention is randomized, and written informed consent obtained from the patient as soon as he regains consciousness. This practice is consistent with the French law for clinical research.
Exclusion Criteria:
- Age < 18 years
- Pregnancy
- Chronic hemodialysis prior to heart surgery
- Body weight >120 kg
- Moribund state, defined as SAPS 2 score> 90
- Severe underlying disease with survival expectancy of less than 8 days
- Decision to withhold or withdraw active therapeutics
- PrismaFlex machine unavailable in the unit
- Intravascular access with dialysis catheter impossible -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: standard care
|
extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:
|
Experimental: high volume hemofiltration
|
(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery.
Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min.
In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being <35 ml/kg/h (or a maximum of 3500 ml/h).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Death from all causes at 30 days after randomisation
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality 60 days following study enrollment
Time Frame: 60 days
|
60 days
|
ICU mortality
Time Frame: 90 days
|
90 days
|
Mortality adjusted on the type of surgery and patient severity at randomization
Time Frame: 90 days
|
90 days
|
Mortality 90 days following study enrollment
Time Frame: 90 days
|
90 days
|
Hospital mortality
Time Frame: 90 days
|
90 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alain Combes, MD PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P071223
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shock
-
Assistance Publique - Hôpitaux de ParisTraumabase Group; Capgemini Invent; Ecole polytechnique; EHESS (Ecole des hautes... and other collaboratorsRecruitingWounds and Injuries | Hemorrhagic Shock | Traumatic ShockFrance
-
Biomedizinische Forschungs gmbHMedical University of ViennaCompletedSepsis | Toxic-Shock Syndrome
-
King's College Hospital NHS TrustUniversity Hospital BirminghamCompletedTraumatic Haemorrhagic ShockUnited Kingdom
-
Haukeland University HospitalMinistry of Defence, NorwayCompletedHemorrhagic Shock | Hypovolemic ShockNorway
-
National Institute of Allergy and Infectious Diseases...Completed
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Boston Medical Center; Tufts Medical Center and other collaboratorsRecruiting
-
Jason SperryNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHemorrhagic ShockUnited States
-
University of Texas Southwestern Medical CenterUniversity of Washington; Resuscitation Outcomes ConsortiumCompletedHemorrhagic ShockUnited States
-
Ramathibodi HospitalUnknownSeptic Shock | Refractory ShockThailand
-
Assiut UniversityUnknown
Clinical Trials on high volume hemofiltration
-
Zhejiang UniversityCompletedOptimal Intensity of Renal Replacement Therapy on Sepsis PatientsChina
-
Air Force Military Medical University, ChinaUnknown
-
University of WashingtonCompletedCardiac ArrestUnited States
-
AHS Cancer Control AlbertaCompleted
-
Peking University Third HospitalRecruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Amsterdam UMC, location VUmc; Leiden University Medical Center; Gelre Hospitals; Tergooi Hospital and other collaboratorsCompleted
-
Inje UniversityCompletedColonoscopy | Bowel PreparationKorea, Republic of
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS); TIRR Memorial... and other collaboratorsRecruitingSpinal Cord InjuriesUnited States
-
American Burn AssociationUniversity of Kansas Medical Center; University of Texas Southwestern Medical... and other collaboratorsUnknownBurns | Shock, Septic | Kidney Failure, Acute | HemofiltrationUnited States
-
Universitätsklinikum Hamburg-EppendorfUnknownPulmonary Ventilation; Newborn, AbnormalGermany